Aspirin-exacerbated respiratory disease (AERD) is a chronic condition characterized by the presence of asthma, chronic rhinosinusitis with nasal polyposis, and sensitivity to aspirin and other non-steroidal anti-inflammatory drugs. Diagnosis is based on careful clinical history and physical examination, characteristic laboratory and radiographic findings, and, in unclear cases, aspirin challenge. Established treatment is founded on comprehensive endoscopic sinus surgery followed by topical steroids and aspirin desensitization. T2 biologics are now available for refractory cases.
Objective
To summarize the historic literature on AERD, its diagnosis and treatment options, as well as to review the most current publications on the topic and explore areas for future research.
Methods
A literature review utilizing the PubMed database was performed.
Results
Seminal journal articles regarding the diagnosis and treatment of AERD were reviewed with close attention to evidence-based protocols and knowledge gaps in the field as areas for future research.
Conclusion
AERD is a complex disease which requires careful diagnostic work-up and coordinated care between the allergist and rhinologist to facilitate optimal treatment outcomes.
BlackwellDLLucasJWClarkeTC. Summary health statistics for U.S. adults: National health interview survey, 2012. Vital Health Stat. 2014;10(260):1–161.
2.
RayNFBaraniukJNThamerM, et al.Healthcare expenditures for sinusitis in 1996: Contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol.1999;103(3 Pt 1):408–414.
3.
GenowayKAPhilpottCMJaverAR. Pathogen yield and antimicrobial resistance patterns of chronic rhinosinusitis patients presenting to a tertiary rhinology centre. J Otolaryngol Head Neck Surg. 2011;40(3):232–237.
4.
GliklichREMetsonR. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg. 1995;113(1):104–109.
5.
Berges-GimenoMPSimonRAStevensonDD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002;89(5):474–478.
6.
RajanJPWineingerNEStevensonDDWhiteAA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol.2015;135(3):676–681.e1.
7.
CahillKNJohnsCBCuiJ, et al.Automated identification of an aspirin-exacerbated respiratory disease cohort. J Allergy Clin Immunol.2017;139(3):819–825.e6.
8.
FahrenholzJM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol. 2003;24(2):113–124.
9.
CardetJCWhiteAABarrettNA, et al.Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2014;2(2):208–213.
10.
NewmanLJPlatts-MillsTAPhillipsCDHazenKCGrossCW. Chronic sinusitis. Relationship of computed tomographic findings to allergy, asthma, and eosinophilia. Jama. 1994;271(5):363–367.
11.
ChangJEDingDMartin-LazaroJWhiteAStevensonDD. Smoking, environmental tobacco smoke, and aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2012;108(1):14–19.
12.
LaidlawTMBoyceJA. Platelets in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol.2015;135(6):1407–1414.
13.
LaidlawTMBoyceJA. Aspirin-exacerbated respiratory disease--new prime suspects. N Engl J Med. 2016;374(5):484–488.
14.
LylyALaidlawTMLundbergM. Pathomechanisms of AERD-recent advances. Front Allergy. 2021;2:734733.
15.
CivantosAMMainaIWArnoldM, et al.Denatonium benzoate bitter taste perception in chronic rhinosinusitis subgroups. Int Forum Allergy Rhinol. 2020;11(6):967–975.
16.
KohanskiMAWorkmanADPatelNN, et al.Solitary chemosensory cells are a primary epithelial source of IL-25 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol.2018;142(2):460–469.e7.
17.
LiuTKanaokaYBarrettNA, et al.Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. The Journal of Immunology. 2015;195(8):3537–3545.
18.
MasciaKHaselkornTDenizYMMillerDPBleeckerERBorishL. Aspirin sensitivity and severity of asthma: Evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol.2005;116(5):970–975.
19.
PsaltisAJLiGVaezeafsharRChoKSHwangPH. Modification of the Lund-Kennedy endoscopic scoring system improves its reliability and correlation with patient-reported outcome measures. Laryngoscope. 2014;124(10):2216–2223.
FountainCRMuddPARamakrishnanVRSillauSHKingdomTTKatialRK. Characterization and treatment of patients with chronic rhinosinusitis and nasal polyps. Ann Allergy Asthma Immunol. 2013;111(5):337–341.
22.
BochenekGStachuraTSzafraniecK, et al.Diagnostic accuracy of urinary LTE4 measurement to predict aspirin-exacerbated respiratory disease in patients with asthma. J Allergy Clin Immunol Pract. 2018;6(2):528–535.
23.
ParkHSKowalskiMLaidlawT. Hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. In: BurksAWO’HehirREBroideDHBacharierLBKhurana HersheyGKPeeblesRS, eds. Middleton’s allergy: principles and practice. 9th ed. Elsevier; 2020:1283–1292.
24.
LeeDKHaggartKRobbFMLipworthBJ. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J. 2004;24(2):226–230.
25.
Lee-SarwarKJohnsCLaidlawTMCahillKN. Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(3):449–451.
26.
JerschowEEdinMLChiY, et al.Sinus surgery is associated with a decrease in aspirin-induced reaction severity in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2019;7(5):1580–1588.
27.
DeGregorioGASingerJCahillKNLaidlawT. A 1-day, 90–Minute aspirin challenge and desensitization protocol in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2019;7(4):1174–1180.
28.
DursunABWoessnerKASimonRAKarasoyDStevensonDD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol. 2008;100(5):420–425.
29.
CookKAModenaBDWineingerNEWoessnerKMSimonRAWhiteAA. Use of a composite symptom score during challenge in patients with suspected aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2017;118(5):597–602.
30.
StevensWWJerschowEBaptistAP, et al.The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A work group report from the rhinitis, rhinosinusitis and ocular allergy committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol.2021;147(3):827–844.
31.
MalfitanoMJSantarelliGDGelpiM, et al.A comparison of sphenoid sinus osteoneogenesis in aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2021;35(2):172–178.
32.
YamashitaTTsujiHMaedaNTomodaKKumazawaT. Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinol Suppl. 1989;8:15–24.
33.
CowburnASSladekKSojaJ, et al.Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest.1998;101(4):834–846.
34.
SweisAMLockeTBIg-IzevbekhaiKI, et al.Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease. Allergy and Asthma Proceedings : The Official Journal of Regional and State Allergy Societies. 2021;42(2):136–141.
35.
LockeTSweisALinT, et al.The impact of endoscopic sinus surgery and aspirin desensitization on psychological burden in aspirin-exacerbated respiratory disease. World J Otorhinolaryngol Head Neck Surg. 2020;6(4):214–219.
36.
BossoJVLockeTBKuanEC, et al.Complete endoscopic sinus surgery followed by aspirin desensitization is associated with decreased overall corticosteroid use. Int Forum Allergy Rhinol. 2020;10(9):1043–1048.
37.
SettipaneRAStevensonDD. Cross sensitivity with Acetaminophen in aspirin-sensitive subjects with asthma. J Allergy Clin Immunol.1989;84(1):26–33.
38.
WoessnerKMSimonRAStevensonDD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum. 2002;46(8):2201–2206.
39.
SchneiderTRJohnsCBPalumboMLMurphyKCCahillKNLaidlawTM. Dietary fatty acid modification for the treatment of aspirin-exacerbated respiratory disease: A prospective pilot trial. J Allergy Clin Immunol Pract. 2018;6(3):825–831.
40.
CloutierMMBaptistAPBlakeKV, et al.2020 Focused updates to the asthma management guidelines: A report from the national asthma education and prevention program coordinating committee expert panel working group. J Allergy Clin Immunol.2020;146(6):1217–1270.
41.
Global Initiative for Asthma [Internet]. Global Strategy for Asthma Management and Prevention. 2022. Available from: www.ginasthma.org.
42.
SweisAMLockeTBDouglasJE, et al.Management of chronic rhinosinusitis with steroid nasal irrigations: A viable nonsurgical alternative in the COVID-19 era. Int Forum Allergy Rhinol. 2020;10(9):1108–1109.
43.
DahlénSEMalmströmKNizankowskaE, et al.Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med.2002;165(1):9–14.
44.
ChristiePESmithCMLeeTH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis.1991;144(4):957–958.
45.
DahlénBNizankowskaESzczeklikA, et al.Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med.1998;157(4 Pt 1):1187–1194.
46.
IsraelEFischerARRosenbergMA, et al.The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis.1993;148(6 Pt 1):1447–1451.
MuhonenEGGoshtasbiKPapagiannopoulosPKuanEC. Appropriate extent of surgery for aspirin-exacerbated respiratory disease. World J Otorhinolaryngol Head Neck Surg. 2020;6(4):235–240.
49.
TimmermansMHellingsPWJorissenM. Draf III frontal sinusotomy: Influence of patient characteristics on outcome. B-ent. 2016;12(2):89–94.
50.
AdappaNDRanasingheVJTropeM, et al.Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2018;8(1):49–53.
51.
TajudeenBASchwartzJSBossoJV. The role of aspirin desensitization in the management of aspirin-exacerbated respiratory disease. Curr Opin Otolaryngol Head Neck Surg.2017;25(1):30–34.
52.
RyanLSegarraDTaborMParasherA. Systematic review of outcomes for endoscopic sinus surgery and subsequent aspirin desensitization in aspirin-exacerbated respiratory disease. World J Otorhinolaryngol Head Neck Surg. 2020;6(4):220–229.
53.
LeeRUWhiteAADingD, et al.Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2010;105(2):130–135.
54.
RozsasiAPolzehlDDeutschleT, et al.Long-term treatment with aspirin desensitization: A prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008;63(9):1228–1234.
55.
PleskowWWStevensonDDMathisonDASimonRASchatzMZeigerRS. Aspirin desensitization in aspirin-sensitive asthmatic patients: Clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol.1982;69(1 Pt 1):11–19.
56.
LockeTBSweisAMGleesonPK, et al.Age as a factor in treatment of aspirin-exacerbated respiratory disease: Relationship to required aspirin maintenance dose after desensitization. Int Forum Allergy Rhinol. 2020;10(10):1180–1181.
57.
TripathiSHKumarAKohanskiMA, et al.Comparison of aspirin desensitization outcomes between men and women with AERD. Int Forum Allergy Rhinol. 2022;12(6):872–875.
58.
CaiZKwintkiewiczJYoungMEStoccoC. Prostaglandin E2 increases cyp19 expression in rat granulosa cells: Implication of GATA-4. Mol Cell Endocrinol. 2007;263(1-2):181–189.
59.
BossoJV. Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: Clinical perspective. Int Forum Allergy Rhinol. 2021;11(4):822–823.
60.
LaidlawTMMullolJFanC, et al.Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract. 2019;7(7):2462–2465.e1.
61.
JeanTEngVSheikhJ, et al.Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease. Allergy and Asthma Proceedings : The Official Journal of Regional and State Allergy Societies. 2019;40(5):316–320.
62.
HayashiHFukutomiYMitsuiC, et al.Omalizumab for Aspirin Hypersensitivity and Leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial. Am J Respir Crit Care Med.2020;201(12):1488–1498.
63.
TuttleKLBuchheitKMLaidlawTMCahillKN. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2018;6(3):1045–1047.
64.
AndersonWCSzeflerSJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?Ann Allergy Asthma Immunol. 2019;122(4):367–372.
65.
YongMWuYQHowlettJBallreichJWalgamaEThambooA. Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2021;11(12):1626–1636.
66.
DouglasJELinCMansfieldCJ, et al.Genetics of denatonium-responsive bitter receptors in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2022.
